Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.07 | 0.22 | -0.55 |
| FCF Yield | 0.00% | 3.29% | 1.65% | 2.20% |
| EV / EBITDA | 2,023.09 | 43.51 | 98.16 | 43.57 |
| Quality | ||||
| ROIC | -5.53% | 1.35% | -1.94% | 1.15% |
| Gross Margin | 90.13% | 76.94% | 89.48% | 85.01% |
| Cash Conversion Ratio | – | 2.60 | -2.59 | 2.90 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.74% | 1.61% | -0.02% | -0.27% |
| Free Cash Flow Growth | 0.00% | 91.86% | -31.50% | -17.12% |
| Safety | ||||
| Net Debt / EBITDA | 2,069.73 | -2.97 | -4.70 | -0.78 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.24 | 0.87 | 0.32 | 0.48 |
| Cash Conversion Cycle | 376.36 | 161.09 | 329.29 | 244.83 |